Pontine μ-opioid receptors mediate bradypnea caused by intravenous remifentanil infusions at clinically relevant concentrations in dogs
Life-threatening side effects such as profound bradypnea or apnea and variable upper airway obstruction limit the use of opioids for analgesia. It is yet unclear which sites containing μ-opioid receptors (μORs) within the intact in vivo mammalian respiratory control network are responsible. The purp...
Saved in:
Published in | Journal of neurophysiology Vol. 108; no. 9; pp. 2430 - 2441 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Physiological Society
01.11.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Life-threatening side effects such as profound bradypnea or apnea and variable upper airway obstruction limit the use of opioids for analgesia. It is yet unclear which sites containing μ-opioid receptors (μORs) within the intact in vivo mammalian respiratory control network are responsible. The purpose of this study was 1) to define the pontine region in which μOR agonists produce bradypnea and 2) to determine whether antagonism of those μORs reverses bradypnea produced by intravenous remifentanil (remi; 0.1-1.0 μg·kg(-1)·min(-1)). The effects of microinjections of agonist [D-Ala(2),N-Me-Phe(4),Gly-ol(5)]-enkephalin (DAMGO; 100 μM) and antagonist naloxone (NAL; 100 μM) into the dorsal rostral pons on the phrenic neurogram were studied in a decerebrate, vagotomized, ventilated, paralyzed canine preparation during hyperoxia. A 1-mm grid pattern of microinjections was used. The DAMGO-sensitive region extended from 5 to 7 mm lateral of midline and from 0 to 2 mm caudal of the inferior colliculus at a depth of 3-4 mm. During remi-induced bradypnea (~72% reduction in fictive breathing rate) NAL microinjections (~500 nl each) within the region defined by the DAMGO protocol were able to reverse bradypnea by 47% (SD 48.0%) per microinjection, with 13 of 84 microinjections producing complete reversal. Histological examination of fluorescent microsphere injections shows that the sensitive region corresponds to the parabrachial/Kölliker-Fuse complex. |
---|---|
AbstractList | Life-threatening side effects such as profound bradypnea or apnea and variable upper airway obstruction limit the use of opioids for analgesia. It is yet unclear which sites containing μ-opioid receptors (μORs) within the intact in vivo mammalian respiratory control network are responsible. The purpose of this study was
1
) to define the pontine region in which μOR agonists produce bradypnea and
2
) to determine whether antagonism of those μORs reverses bradypnea produced by intravenous remifentanil (remi; 0.1–1.0 μg·kg
−1
·min
−1
). The effects of microinjections of agonist [
d
-Ala
2
,
N
-Me-Phe
4
,Gly-ol
5
]-enkephalin (DAMGO; 100 μM) and antagonist naloxone (NAL; 100 μM) into the dorsal rostral pons on the phrenic neurogram were studied in a decerebrate, vagotomized, ventilated, paralyzed canine preparation during hyperoxia. A 1-mm grid pattern of microinjections was used. The DAMGO-sensitive region extended from 5 to 7 mm lateral of midline and from 0 to 2 mm caudal of the inferior colliculus at a depth of 3–4 mm. During remi-induced bradypnea (∼72% reduction in fictive breathing rate) NAL microinjections (∼500 nl each) within the region defined by the DAMGO protocol were able to reverse bradypnea by 47% (SD 48.0%) per microinjection, with 13 of 84 microinjections producing complete reversal. Histological examination of fluorescent microsphere injections shows that the sensitive region corresponds to the parabrachial/Kölliker-Fuse complex. Life-threatening side effects such as profound bradypnea or apnea and variable upper airway obstruction limit the use of opioids for analgesia. It is yet unclear which sites containing μ-opioid receptors (μORs) within the intact in vivo mammalian respiratory control network are responsible. The purpose of this study was 1) to define the pontine region in which μOR agonists produce bradypnea and 2) to determine whether antagonism of those μORs reverses bradypnea produced by intravenous remifentanil (remi; 0.1–1.0 μg·kg −1 ·min −1 ). The effects of microinjections of agonist [d-Ala 2 , N-Me-Phe 4 ,Gly-ol 5 ]-enkephalin (DAMGO; 100 μM) and antagonist naloxone (NAL; 100 μM) into the dorsal rostral pons on the phrenic neurogram were studied in a decerebrate, vagotomized, ventilated, paralyzed canine preparation during hyperoxia. A 1-mm grid pattern of microinjections was used. The DAMGO-sensitive region extended from 5 to 7 mm lateral of midline and from 0 to 2 mm caudal of the inferior colliculus at a depth of 3–4 mm. During remi-induced bradypnea (∼72% reduction in fictive breathing rate) NAL microinjections (∼500 nl each) within the region defined by the DAMGO protocol were able to reverse bradypnea by 47% (SD 48.0%) per microinjection, with 13 of 84 microinjections producing complete reversal. Histological examination of fluorescent microsphere injections shows that the sensitive region corresponds to the parabrachial/Kölliker-Fuse complex. Life-threatening side effects such as profound bradypnea or apnea and variable upper airway obstruction limit the use of opioids for analgesia. It is yet unclear which sites containing μ-opioid receptors (μORs) within the intact in vivo mammalian respiratory control network are responsible. The purpose of this study was 1) to define the pontine region in which μOR agonists produce bradypnea and 2) to determine whether antagonism of those μORs reverses bradypnea produced by intravenous remifentanil (remi; 0.1-1.0 μg·kg(-1)·min(-1)). The effects of microinjections of agonist [D-Ala(2),N-Me-Phe(4),Gly-ol(5)]-enkephalin (DAMGO; 100 μM) and antagonist naloxone (NAL; 100 μM) into the dorsal rostral pons on the phrenic neurogram were studied in a decerebrate, vagotomized, ventilated, paralyzed canine preparation during hyperoxia. A 1-mm grid pattern of microinjections was used. The DAMGO-sensitive region extended from 5 to 7 mm lateral of midline and from 0 to 2 mm caudal of the inferior colliculus at a depth of 3-4 mm. During remi-induced bradypnea (~72% reduction in fictive breathing rate) NAL microinjections (~500 nl each) within the region defined by the DAMGO protocol were able to reverse bradypnea by 47% (SD 48.0%) per microinjection, with 13 of 84 microinjections producing complete reversal. Histological examination of fluorescent microsphere injections shows that the sensitive region corresponds to the parabrachial/Kölliker-Fuse complex. |
Author | Hopp, Francis A Dean, Caron Mustapic, Sanda Stucke, Astrid G Radocaj, Tomislav Prkic, Ivana Stuth, Eckehard A E Zuperku, Edward J |
Author_xml | – sequence: 1 givenname: Ivana surname: Prkic fullname: Prkic, Ivana organization: Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA – sequence: 2 givenname: Sanda surname: Mustapic fullname: Mustapic, Sanda – sequence: 3 givenname: Tomislav surname: Radocaj fullname: Radocaj, Tomislav – sequence: 4 givenname: Astrid G surname: Stucke fullname: Stucke, Astrid G – sequence: 5 givenname: Eckehard A E surname: Stuth fullname: Stuth, Eckehard A E – sequence: 6 givenname: Francis A surname: Hopp fullname: Hopp, Francis A – sequence: 7 givenname: Caron surname: Dean fullname: Dean, Caron – sequence: 8 givenname: Edward J surname: Zuperku fullname: Zuperku, Edward J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22875901$$D View this record in MEDLINE/PubMed |
BookMark | eNpVUUFu2zAQJIoUjZP22GvAD8hdUmYkXQIEQdIWCNAe2jOxIpcpDXkpiLIB_yCPyhv6ptJxG6SnXczOzO5izsQJJyYhPipYKmX0pzUvAVRrlhqUfiMWBdOVMl17IhYApa-haU7FWc5rAGgM6HfiVOu2MR2ohXj8nniOTPL3U5XGmKKXEzka5zRluSEfcSbZT-j3IxNKh9tMXvZ7GXmecEectrkoNjEQz8hxKIOwzTFxljhLN0SODodhX0gD7ZALltjRQT0_syJLnx7ye_E24JDpw996Ln7e3f64-VLdf_v89eb6vnKrWs2Vb7EPfa_NpWtp5RuHnYc-eN-E7rKjHqirQw3QYqcdmUa3BTYhqBrJo1L1ubg6-o7bvvx3vGSw4xQ3OO1twmj_n3D8ZR_SztZmZVQLxaA6Grgp5TxReNEqsIdI7JrtcyT2EEnhX7xe-ML-l0H9B8QWkHY |
CitedBy_id | crossref_primary_10_1016_j_resp_2020_103388 crossref_primary_10_1097_ALN_0000000000001719 crossref_primary_10_1097_ALN_0000000000000628 crossref_primary_10_1097_j_pain_0000000000002802 crossref_primary_10_1016_j_ejphar_2017_06_012 crossref_primary_10_21307_ijssis_2019_083 crossref_primary_10_1016_j_neuron_2021_11_029 crossref_primary_10_1152_ajpregu_00120_2016 crossref_primary_10_1152_japplphysiol_00819_2021 crossref_primary_10_1113_JP270822 crossref_primary_10_3389_fphys_2023_1156076 crossref_primary_10_1097_ALN_0000000000000984 crossref_primary_10_1113_jphysiol_2013_268318 crossref_primary_10_1016_j_resp_2018_06_011 crossref_primary_10_1016_j_resp_2020_103428 crossref_primary_10_1016_j_bpa_2017_05_004 crossref_primary_10_1113_jphysiol_2013_268300 crossref_primary_10_1152_physiol_00015_2020 crossref_primary_10_3389_fphys_2019_01407 crossref_primary_10_1002_cne_25136 crossref_primary_10_1038_s41598_019_50613_2 crossref_primary_10_1073_pnas_2022134118 crossref_primary_10_1152_jn_00478_2023 crossref_primary_10_1111_bph_15580 crossref_primary_10_1113_jphysiol_2013_258830 crossref_primary_10_7554_eLife_67523 crossref_primary_10_1097_ALN_0000000000003886 crossref_primary_10_1590_0103_8478cr20230020 crossref_primary_10_1016_j_resp_2022_103855 crossref_primary_10_7554_eLife_50613 crossref_primary_10_1016_j_resp_2020_103401 crossref_primary_10_1016_j_bja_2018_12_023 crossref_primary_10_1016_j_resp_2020_103482 crossref_primary_10_1002_cne_25307 crossref_primary_10_1002_jnr_24636 crossref_primary_10_1016_j_resp_2014_11_016 crossref_primary_10_1124_mol_117_109603 crossref_primary_10_1523_ENEURO_0035_23_2023 crossref_primary_10_1016_j_neuropharm_2017_12_032 crossref_primary_10_1016_j_peptides_2013_10_001 crossref_primary_10_1016_j_resp_2015_03_005 crossref_primary_10_7554_eLife_81119 crossref_primary_10_1152_jn_00017_2021 crossref_primary_10_1016_j_eclinm_2023_102417 crossref_primary_10_1038_s41467_018_08162_1 crossref_primary_10_1523_JNEUROSCI_1329_21_2021 crossref_primary_10_7554_eLife_52694 crossref_primary_10_1152_jn_00591_2016 crossref_primary_10_1371_journal_pone_0153187 crossref_primary_10_1113_jphysiol_2013_261974 crossref_primary_10_1111_jnc_15041 crossref_primary_10_2174_1570159X21666230810110901 crossref_primary_10_1007_s00542_015_2707_0 crossref_primary_10_1152_jn_00113_2022 crossref_primary_10_1007_s00204_022_03300_7 crossref_primary_10_1113_JP278612 crossref_primary_10_1016_j_resp_2021_103736 crossref_primary_10_1016_j_crtox_2022_100078 crossref_primary_10_1111_adb_13350 crossref_primary_10_3389_fphys_2023_1109754 |
Cites_doi | 10.1124/jpet.104.082560 10.1016/j.resp.2004.07.019 10.1146/annurev.neuro.25.032502.111311 10.1213/00000539-199609000-00038 10.1097/00000542-199604000-00014 10.1002/(SICI)1096-9861(19960408)367:3<375::AID-CNE5>3.0.CO;2-2 10.1152/jappl.1998.85.2.747 10.1523/JNEUROSCI.4611-10.2011 10.1152/japplphysiol.90548.2008 10.1016/0028-3908(85)90100-5 10.1007/BF00583790 10.1152/physrev.1995.75.1.1 10.1111/j.1476-5381.1988.tb11719.x 10.1097/01.anes.0000270760.46821.67 10.1016/j.resp.2008.10.007 10.1016/S0304-3940(03)00951-0 10.1097/ALN.0b013e31819faa2a 10.1016/j.resp.2008.02.004 10.1152/jn.00188.2009 10.1016/S0952-8180(96)00179-1 10.1016/0006-8993(85)90820-0 10.1016/0891-0618(95)00055-C 10.1080/01621459.1988.10478639 10.1523/JNEUROSCI.1375-09.2009 10.1126/science.286.5444.1566 10.1093/bja/aei058 10.1126/science.1084674 10.1152/jn.00429.2004 10.1038/386499a0 10.1007/s10072-006-0587-x 10.1002/(SICI)1096-9861(19990322)405:4<450::AID-CNE2>3.0.CO;2-# 10.1113/jphysiol.2002.023408 10.1113/jphysiol.1971.sp009563 10.1016/j.jneumeth.2005.11.012 10.1016/S0006-8993(99)01168-3 10.1016/S1569-9048(03)00173-3 10.1016/0006-8993(85)91586-0 10.1523/JNEUROSCI.14-11-06500.1994 10.1113/jphysiol.1994.sp020193 10.1152/jn.90620.2008 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM |
DOI | 10.1152/jn.00185.2012 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 1522-1598 |
EndPage | 2441 |
ExternalDocumentID | 10_1152_jn_00185_2012 22875901 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: BLRD VA grantid: I01 BX000721 – fundername: NIGMS NIH HHS grantid: GM-59234-06A1 |
GroupedDBID | --- -DZ -~X .55 .GJ 0VX 18M 1CY 1Z7 29L 2WC 39C 3O- 4.4 41~ 476 53G 5GY 5VS 8M5 ABCQX ABIVO ABJNI ABKWE ABTAH ACGFO ACGFS ACNCT ADBBV ADFNX ADIYS AENEX AFFNX AFOSN AI. AIZAD ALMA_UNASSIGNED_HOLDINGS BAWUL BKKCC BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EMOBN F5P FRP GX1 H13 H~9 ITBOX KQ8 L7B MVM NEJ NPM OHT OK1 P2P RAP RHF RHI RPL RPRKH SJN TR2 UHB UPT UQL VH1 W8F WH7 WOQ WOW X7M XJT XOL XSW YBH YQT YSK ZGI ZXP ZY4 AAYXX CITATION 5PM AETEA |
ID | FETCH-LOGICAL-c431t-d8abfbb256c8e4d7ca9d0bfdd7f969eb0e93f3008a92ce57289695ff13aeda113 |
ISSN | 0022-3077 |
IngestDate | Tue Sep 17 21:09:53 EDT 2024 Thu Sep 26 15:46:03 EDT 2024 Sat Sep 28 08:34:48 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c431t-d8abfbb256c8e4d7ca9d0bfdd7f969eb0e93f3008a92ce57289695ff13aeda113 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545180 |
PMID | 22875901 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3545180 crossref_primary_10_1152_jn_00185_2012 pubmed_primary_22875901 |
PublicationCentury | 2000 |
PublicationDate | 2012-11-01 |
PublicationDateYYYYMMDD | 2012-11-01 |
PublicationDate_xml | – month: 11 year: 2012 text: 2012-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Bethesda, MD |
PublicationTitle | Journal of neurophysiology |
PublicationTitleAlternate | J Neurophysiol |
PublicationYear | 2012 |
Publisher | American Physiological Society |
Publisher_xml | – name: American Physiological Society |
References | B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B10 B32 B33 B12 B34 B13 B35 B14 B36 B15 B37 B16 B38 B17 B39 Feldman JL (B11) 1986 B18 B19 B1 B2 B3 B4 B5 B6 B7 B8 B9 B40 B41 |
References_xml | – ident: B39 doi: 10.1124/jpet.104.082560 – ident: B17 doi: 10.1016/j.resp.2004.07.019 – ident: B35 doi: 10.1146/annurev.neuro.25.032502.111311 – ident: B3 doi: 10.1213/00000539-199609000-00038 – ident: B27 doi: 10.1097/00000542-199604000-00014 – ident: B9 doi: 10.1002/(SICI)1096-9861(19960408)367:3<375::AID-CNE5>3.0.CO;2-2 – ident: B38 doi: 10.1152/jappl.1998.85.2.747 – start-page: 463 volume-title: Handbook of Physiology. The Nervous System. Intrinsic Regulatory Systems of the Brain. year: 1986 ident: B11 contributor: fullname: Feldman JL – ident: B28 doi: 10.1523/JNEUROSCI.4611-10.2011 – ident: B19 doi: 10.1152/japplphysiol.90548.2008 – ident: B15 doi: 10.1016/0028-3908(85)90100-5 – ident: B10 doi: 10.1007/BF00583790 – ident: B2 doi: 10.1152/physrev.1995.75.1.1 – ident: B6 doi: 10.1111/j.1476-5381.1988.tb11719.x – ident: B41 doi: 10.1097/01.anes.0000270760.46821.67 – ident: B36 doi: 10.1016/j.resp.2008.10.007 – ident: B14 doi: 10.1016/S0304-3940(03)00951-0 – ident: B33 doi: 10.1097/ALN.0b013e31819faa2a – ident: B20 doi: 10.1016/j.resp.2008.02.004 – ident: B29 doi: 10.1152/jn.00188.2009 – ident: B26 doi: 10.1016/S0952-8180(96)00179-1 – ident: B34 doi: 10.1016/0006-8993(85)90820-0 – ident: B23 doi: 10.1016/0891-0618(95)00055-C – ident: B7 doi: 10.1080/01621459.1988.10478639 – ident: B31 doi: 10.1523/JNEUROSCI.1375-09.2009 – ident: B13 doi: 10.1126/science.286.5444.1566 – ident: B18 doi: 10.1093/bja/aei058 – ident: B24 doi: 10.1126/science.1084674 – ident: B12 doi: 10.1152/jn.00429.2004 – ident: B40 doi: 10.1038/386499a0 – ident: B1 doi: 10.1007/s10072-006-0587-x – ident: B25 doi: 10.1002/(SICI)1096-9861(19990322)405:4<450::AID-CNE2>3.0.CO;2-# – ident: B16 doi: 10.1113/jphysiol.2002.023408 – ident: B8 doi: 10.1113/jphysiol.1971.sp009563 – ident: B32 doi: 10.1016/j.jneumeth.2005.11.012 – ident: B4 doi: 10.1016/S0006-8993(99)01168-3 – ident: B22 doi: 10.1016/S1569-9048(03)00173-3 – ident: B30 doi: 10.1016/0006-8993(85)91586-0 – ident: B5 doi: 10.1523/JNEUROSCI.14-11-06500.1994 – ident: B21 doi: 10.1113/jphysiol.1994.sp020193 – ident: B37 doi: 10.1152/jn.90620.2008 |
SSID | ssj0007502 |
Score | 2.3844988 |
Snippet | Life-threatening side effects such as profound bradypnea or apnea and variable upper airway obstruction limit the use of opioids for analgesia. It is yet... |
SourceID | pubmedcentral crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 2430 |
SubjectTerms | Analgesics, Opioid - toxicity Anesthetics, Intravenous - toxicity Animals Brain Mapping Diaphragm - innervation Dogs Enkephalin, Ala-MePhe-Gly- - pharmacology Hyperoxia Infusions, Intravenous Naloxone - pharmacology Narcotic Antagonists - pharmacology Phrenic Nerve - physiology Piperidines - toxicity Pons - drug effects Pons - metabolism Pons - physiology Receptors, Opioid, mu - agonists Receptors, Opioid, mu - antagonists & inhibitors Receptors, Opioid, mu - metabolism Remifentanil Respiratory Rate - drug effects Respiratory Rate - physiology |
Title | Pontine μ-opioid receptors mediate bradypnea caused by intravenous remifentanil infusions at clinically relevant concentrations in dogs |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22875901 https://pubmed.ncbi.nlm.nih.gov/PMC3545180 |
Volume | 108 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NctMwENaEcuHCAOUn_I0O0EvGJZGt2DqWTKHAwARIZ3rLSJY8dWntTOp0JjwBD8WFF-CZ2JUV2aY9FC6eWP5LvF-kT6vdbwl5EUpjmNBZwFDqMzJSBYrDrszUkHOWCiHRD_nx0_jgMHp_xI96vV-tqKVVpXbT71fmlfyPVaEN7IpZsv9gWX9TaIDPYF_YgoVhey0bT0us8wAscbL_8vUkKBd5mWM2CoaqYBEdmxZSmQHMiPV6URg5SOXqvOacOXp1L2qF1qU5yzMMIi9ylODIVuc2PE5WPnHydG2rqwDtrjBQvQ7p9GHounTe9sss1-plWvdJx38_XX7LbW31d1jUubE6cNVFfeCrbDkLvkgNY65daJqVgMxTeeFdQxVGhtguDkuQ6MHb3bYnY8RcSl-rd8bMgqEr62JchwxtQLmSTo89TFrQFO3-N3KrPMbt1qpal8cJjrqzJwUuRCUcI_xYMyBuggD-Gid99KKdN3E2Pynm9vI5Xn6D3GSx4Dj___C5EawHQtYI1sNP28i8cvaq8_QOLfJcqBun2yI-szvktrMl3avhd5f0THGPbO8VsirP1nSHTr1xt8kPh0j6-6dDI_VopA6N1KOR1mikak1baKRtNFKPRior2qCRbtBIu2iE8ymi8T45fLM_mxwErtZHkAKFrQKdSJUpBQQ8TUyk41QKPVSZ1nEmxsKooRFhFgJhlYKlhscsgWaeZSPobLQcjcIHZKsoC_OI0DGmwHIBFycsklIlOrQydXyUcphvpH2ys3nV80Ut6TK_0qR98rB-__40xmB6Dwy6T-KOZfwJKNbePVLkx1a0PYSpCnyJx9d9-BNyq_mPPCVb1XJlngH_rdRzi7A_9Ze7Rg |
link.rule.ids | 230,315,786,790,891,27957,27958 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pontine+%CE%BC-opioid+receptors+mediate+bradypnea+caused+by+intravenous+remifentanil+infusions+at+clinically+relevant+concentrations+in+dogs&rft.jtitle=Journal+of+neurophysiology&rft.au=Prkic%2C+Ivana&rft.au=Mustapic%2C+Sanda&rft.au=Radocaj%2C+Tomislav&rft.au=Stucke%2C+Astrid+G.&rft.date=2012-11-01&rft.issn=0022-3077&rft.eissn=1522-1598&rft.volume=108&rft.issue=9&rft.spage=2430&rft.epage=2441&rft_id=info:doi/10.1152%2Fjn.00185.2012&rft.externalDBID=n%2Fa&rft.externalDocID=10_1152_jn_00185_2012 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3077&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3077&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3077&client=summon |